Invex Therapeutics (ASX:IXC) Ending Cash Position : A$6.15 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Ending Cash Position?

Invex Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was A$6.15 Mil.

Invex Therapeutics's quarterly Ending Cash Position declined from Dec. 2022 (A$25.42 Mil) to Jun. 2023 (A$22.47 Mil) and declined from Jun. 2023 (A$22.47 Mil) to Dec. 2023 (A$6.15 Mil).

Invex Therapeutics's annual Ending Cash Position declined from Jun. 2021 (A$32.72 Mil) to Jun. 2022 (A$29.34 Mil) and declined from Jun. 2022 (A$29.34 Mil) to Jun. 2023 (A$22.47 Mil).

Invex Therapeutics Ending Cash Position Historical Data

The historical data trend for Invex Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Ending Cash Position Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Ending Cash Position

26.30

32.72

29.34

22.47

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial				31.37	29.34	25.42	22.47	6.15

Invex Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Invex Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	29.339	+	-6.869
	=	22.47

Invex Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	22.47	+	-16.318
	=	6.15

Invex Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics (ASX:IXC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.